REGULATORY
FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027The FDA has extended its approval decision for Exelixis' oral kinase inhibitor zanzalintinib in combination with Roche's Tecentriq to March 2027 while awaiting updated safety and efficacy data, after the drug missed one primary endpoint measuring overall survival in a subpopulation earlier this year. (Fierce Biotech)